Company Encyclopedia
View More
name
Bluejay Diagnostics
BJDX.US
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis.
1.391 T
BJDX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Bluejay Diagnostics Reports Q3 Results and Updates

    Bluejay Diagnostics (BJDX) reported its Q3 results on November 10, 2025, highlighting advancements in clinical trials and strategic partnerships. The company is focused on sepsis diagnostics and plans to submit a 510(k) application to the FDA in 2027. However, BJDX is rated as Underperform by TipRanks’ AI Analyst due to poor financial performance, lack of revenue, and continuous losses. The stock shows a bearish trend, with a current market cap of $2.85M and an average trading volume of 4,115,858.

    Tip Ranks·
    US
    BJDX
    -4.00%
    Tip Ranks·
    US
    BJDX
    -4.00%

    Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships

    ACTON, Mass., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Bluejay Diagnostics, Inc. ( NASDAQ: BJDX ) ( "Bluejay" or the "Company" ) , a medical diagnostics company developing near-patient testing solutions for critical care, announced financial results for the quarter ended September 30, 2025, and ...

    GlobeNewswire·
    US
    BJDX
    -4.00%
    GlobeNewswire·
    US
    BJDX
    -4.00%

    Bluejay Diagnostics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BJDX
    -4.00%
    LB filings·
    US
    BJDX
    -4.00%

    Bluejay Diagnostics Inc - Enters Into Securities Purchase Agreement On Oct 9 - SEC Filing

    Oct 14 (Reuters) - Bluejay Diagnostics Inc:* BLUEJAY DIAGNOSTICS INC - ENTERS INTO SECURITIES PURCHASE AGREEMENT ON OCT 9 - SEC FILING* BLUEJAY DIAGNOSTICS INC - PRIVATE PLACEMENT CLOSED ON OCTOBER 10, 2025 - SEC FILING Source text: Further company coverage:

    Reuters·
    US
    BJDX
    -4.00%
    Reuters·
    US
    BJDX
    -4.00%

    Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    Bluejay Diagnostics Inc. has announced a $4.5 million private placement priced at-the-market under Nasdaq rules. The company will sell 2,250,000 shares of common stock and Series F warrants to purchase up to 4,500,000 shares at $2.00 per share. The Series F warrants have an exercise price of $1.75 and will expire in 5.5 years. The proceeds will support FDA approval efforts, R&D activities, and general working capital. Rodman and Renshaw LLC is the exclusive placement agent for this offering.

    Reuters·
    US
    BJDX
    -4.00%
    Reuters·
    US
    BJDX
    -4.00%
    © 2025 Longbridge｜Disclaimer